Your search returned 2 results.

Sort
Unhighlight Highlight
Select all Clear all
Select titles to:
Results
1.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 27650977
Year: 2016
Citation:
  • Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
DOI:
Add to cart
2.
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. MedStar authors:
  • Aroda, Vanita R
PMID:
  • 31530665
Year: 2019
Citation:
  • Diabetes Care. 42(11):2108-2116, 2019 11.
Institution:
  • MedStar Health Research Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Aroda VR, Blonde L, Del Prato S, Frias J, Henry R, Ji C, Niemoeller E, Rosenstock J, Shehadeh N, Souhami E
DOI:
Add to cart
Pages

Powered by Koha